Researchers identify Rb1 as a predictive biomarker for a new therapeutic strategy in some breast cancers
Preclinical study identifies Rb1 deficiency as key therapeutic vulnerability in a subset of breast cancers resistant to standard CDK4/6 inhibitors
Drugs that may exploit this vulnerability are already in clinical trials
Rb1-deficient cancers represent nearly 40% of triple-negative and estrogen receptor–positive tumors, which together account for roughly 20% of all breast cancers
Rb1 status could also serve as an important predictive biomarker...
Novel targeted therapy regimens show promise in aggressive AML subtype
MECOM-rearranged acute myeloid leukemia (AML) is an aggressive and hard-to-treat leukemia
Researchers combined three inhibitors...
Promising target improves antitumor response in preclinical models of pancreatic cancer
Mitochondrial enzyme GFER is a key component in creating an immunosuppressive environment in pancreatic cancer
Inhibiting GFER along with...
Inhibiting GFER along with...
Proton therapy shows survival benefit in Phase III trial for patients with head and neck cancers
At five years, 90.9% of proton patients were alive compared to 81% with traditional radiation
Proton therapy also showed benefits in quality of life, such as less feeding tube dependence, less difficulty swallowing, less dry mouth, and higher immune cell counts
Study represents the largest randomized Phase III trial comparing proton to traditional radiation with photons for oropharyngeal cancer patients
A new study published today in...
SABCS 2025: Diagnostic breast MRI may be unnecessary for some patients with early-stage breast cancer
Study finds pre-surgical MRI does not improve five-year rates of local regional free survival over mammograms alone in patients with stage...
ASH 2025: New data highlights promise of pivekimab sunirine in two aggressive blood cancers
Two clinical studies demonstrate high response rates by patients with two hard-to-treat and aggressive blood cancers
Pivekimab...
ASH 2025: Researchers identify CD40 as potential biomarker for a type of nodal T cell lymphoma
Researchers characterized the microenvironment of a nodal T cell lymphoma that is difficult to diagnose and treat
The study...
ASH 2025: Shorter azacitidine regimen safely improves outcomes in lower-risk MDS patients
Azacitidine is a type of targeted therapy known as a hypomethylating agent, commonly used in treating myelodysplastic syndromes (MDS)...
ASH 2025: Results show long-lasting benefits of CAR T cell therapy for hard-to-treat lymphoma
Lisocabtagene maraleucel (liso-cel), a CAR T cell therapy, achieved an overall response rate of 97% in the TRANSCEND FL study
Durable...
ASH 2025: New MD Anderson-developed antibody boosts immune response against blood cancers and solid cancers
New investigational therapy 77A is an antibody that converts a cancer survival protein (HSP70) into an immune system trigger
Targeting...
ASH 2025: CAR T cell therapy shows promising Phase II trial results in multiple myeloma
Anito-cel is an experimental CAR T cell therapy for relapsed/refractory multiple myeloma patients
In updated Phase II trial results...
Researchers identify target to overcome treatment resistance in preclinical models of KRAS-mutant cancers
Researchers identified that RASH3D19 creates a positive feedback loop that drives hyperactivity of RAS signaling and leads to tumor growth and...
Study provides comprehensive insights into DNA language models
Researchers examined five AI models on multiple genomic tasks to see how well they performed
Models performed well overall, with each having...